Study guide
5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas
Key Takeaways Explain This Topic AI
Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma; site drives risk, with parameningeal head and neck carrying CNS invasion risk and orbit generally having a better prognosis.
Embryonal histology is more common in younger children at favorable head-neck and genitourinary sites; alveolar histology with FOXO1 fusion is adverse and more often extremity or trunk disease.
Intergroup Rhabdomyosarcoma Study grouping (complete resection versus microscopic residual versus gross residual versus metastases) plus site-based staging guides intensity of VAC/VA-like chemotherapy and radiation.
VAC/VA-like therapy uses vincristine, dactinomycin, and cyclophosphamide; nursing priorities include mucositis, radiation dermatitis in parameningeal fields, fertility after alkylators, and bladder function after pelvic radiation or surgery.
Non-rhabdomyosarcoma soft-tissue sarcomas include synovial sarcoma in adolescents and infantile fibrosarcoma with NTRK fusions; they are not interchangeable with VAC rhabdomyosarcoma pathways.
Last updated: August 2026
A 4-year-old develops chronic otitis on one side, then a sixth-nerve palsy. The “ear infection” is a parameningeal rhabdomyosarcoma of the middle ear and nasopharynx. A different 18-month-old has a grape-like vaginal mass that bleeds on diapers—botryoid embryonal rhabdomyosarcoma. A 12-year-old has a painless calf mass that is alveolar rhabdomyosarcoma with a FOXO1 fusion. Same family of tumors, three different CPHON maps. Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma . Questions test site, histology and fusion, grouping, VAC/VA-like drugs, and the nursing fallout of radiation and pelvic surgery—not a memorized catalog of every rare sarcoma name.
- Sites that change risk
- Think in anatomic neighborhoods, not “a lump somewhere.”
Head and neck, parameningeal. Parameningeal sites include nasopharynx, paranasal sinuses, middle ear, pterygopalatine and infratemporal fossae, and other locations that abut skull base and meninges. These tumors can invade the central nervous system, produce cranial-nerve palsies, and seed cerebrospinal fluid. Protocol workup commonly includes neuraxis imaging and, when indicated, lumbar puncture. Families should hear that this is not a simple ear or sinus infection even if that is how it started. Radiation is frequently part of local control. Nursing later means radiation dermatitis , mucositis, otitis, dental and salivary changes, and hearing surveillance when the field includes the ear.
Orbit. Orbital rhabdomyosarcoma classically presents with rapidly progressive proptosis and is a more favorable site on cooperative-group risk models. Vision preservation and careful radiation planning still matter, but the exam contrast is orbit versus parameningeal: do not lump every head-and-neck mass into the same prognosis speech.
Genitourinary. Botryoid (“grape-like”) tumors of vagina or bladder occur in infants and young children, usually embryonal histology, and can look like a vaginal foreign body or hematuria. Paratesticular tumors in boys are another genitourinary presentation. Bladder and prostate primaries are less favorable than vagina or paratestes on many schemas. After pelvic radiation or bladder surgery, teach bladder function : capacity, hematuria, continence, urinary tract infection, and the need for urology follow-up—not only “the mass is gone.”
Extremity and trunk. Limb and trunk tumors are more often alveolar, more often fusion-positive, and more often need intensive local control. A teenager’s painless extremity mass is not a sports bruise until imaging and biopsy say so. Regional nodes matter; sentinel or regional sampling follows protocol, not a casual clinic observation.
Embryonal versus alveolar, and FOXO1
Embryonal rhabdomyosarcoma is more common in younger children and at favorable head-neck and genitourinary sites. Alveolar rhabdomyosarcoma is more common in older children, extremities, and trunk. The molecular teaching point is FOXO1 fusion (PAX3-FOXO1 or PAX7-FOXO1). Fusion-positive alveolar disease is worse than typical embryonal disease and drives more intensive therapy and closer metastatic surveillance—lung, bone, marrow, and nodes depending on protocol. Fusion-negative tumors that look alveolar under the microscope may behave more like embryonal disease; the nurse’s teaching point is that fusion status changes risk , not that every alveolar-looking slide is identical.
Do not tell a family that “rhabdomyosarcoma is one chemotherapy recipe.” Site plus group plus fusion is the recipe.
IRS grouping and staging, without a museum of codes
Cooperative-group care still uses Intergroup Rhabdomyosarcoma Study clinical group plus site-based staging :
Group I: complete resection, negative margins.
Group II: microscopic residual disease or completely resected involved nodes.
Group III: gross residual disease (biopsy only or incomplete resection)—the most common group at diagnosis because many sites cannot be fully excised up front.
Group IV: distant metastases.
Staging additionally uses favorable versus unfavorable site, tumor size, nodes, and metastases. Favorable-site examples include orbit, non-parameningeal head and neck, and selected genitourinary sites such as vagina and paratestes. Unfavorable-site examples include parameningeal, bladder/prostate, extremity, trunk, and retroperitoneum. The CPHON job is not to recite every TNM box. It is to explain why a completely resected paratesticular embryonal tumor and a unresected parameningeal alveolar tumor will not share the same intensity, radiation plan, or fertility conversation.
Up-front mutilating surgery is not the goal. Biopsy, risk assignment, chemotherapy, then local control timed to the protocol is the usual sequence except when a small favorable tumor is already completely excised.
VAC/VA-like chemotherapy and radiation
Backbone therapy is VAC or reduced VA : vincristine , dactinomycin (actinomycin D), and cyclophosphamide , with radiation for residual disease, parameningeal sites, many alveolar tumors, and other protocol indications. Vincristine brings constipation, jaw pain, and foot drop—start a bowel regimen before the next weekly dose. Dactinomycin brings mucositis and radiosensitization; do not treat severe oral pain as “picky eating,” and watch skin in the radiation field for enhanced dermatitis. Cyclophosphamide brings myelosuppression, hemorrhagic cystitis risk (hydration and mesna when the protocol uses higher doses), and fertility injury, especially when pelvic radiation is added.
Radiation dermatitis in parameningeal fields involves face, scalp, ear canal, and mucous membranes. Teach gentle skin care, infection watch, and that “tanning” in the field is injury, not a cosmetic issue. After pelvic radiation or bladder/prostate surgery, ask about stream, urgency, incontinence, and sexual-function questions in adolescents in private. Offer fertility counseling before alkylators and pelvic radiation when the child’s developmental stage allows, and always with the parents of younger children so the record is not blank at survivorship clinic.
Fever-neutropenia still applies. A child with a parameningeal tumor and mucositis who spikes a fever is a two-problem emergency: infection plus a potential portal through damaged mucosa.
Non-rhabdomyosarcoma soft-tissue sarcomas, briefly
Not every pediatric soft-tissue mass is rhabdomyosarcoma. Synovial sarcoma typically appears in adolescents near large joints; it is one of the more chemotherapy-responsive non-rhabdomyosarcoma tumors but still needs expert local control. Infantile fibrosarcoma is a tumor of infants, often an extremity mass, classically associated with ETV6-NTRK3; NTRK -directed therapy is the modern teaching concept for unresectable or metastatic NTRK-fusion disease, rather than automatically copying a VAC rhabdomyosarcoma roadmap. Other non-rhabdomyosarcoma tumors (malignant peripheral nerve sheath tumor, undifferentiated sarcoma, and others) are managed on non-rhabdomyosarcoma protocols. The nursing trap is giving rhabdomyosarcoma discharge teaching to a family whose child is not on VAC.
A 3-month-old with a rapidly growing calf mass may have infantile fibrosarcoma, not alveolar rhabdomyosarcoma. A 15-year-old with a mass at the knee may have synovial sarcoma. Send both to a pediatric sarcoma center; do not start adult soft-tissue recipes or rhabdomyosarcoma VAC by habit.
Site or subtype Typical clue Nursing emphasis
Parameningeal head/neck Cranial-nerve palsy, “chronic sinus or otitis” CNS-risk workup, radiation dermatitis, mucositis
Orbit Rapid proptosis Generally better prognosis; protect vision and irradiated skin
GU botryoid (vagina/bladder) Grape-like mass, vaginal bleeding, hematuria in a toddler Embryonal often; later bladder function and fertility
Extremity / trunk alveolar, FOXO1+ Painless limb or trunk mass in a school-age child or teen Higher-risk local control and metastatic surveillance
IRS Group III vs I Biopsy only versus complete resection Gross residual disease usually needs radiation plus full VAC intensity
Infantile fibrosarcoma Infant extremity mass, NTRK fusion Not automatic VAC; NTRK-directed concept if unresectable
Synovial sarcoma Adolescent periarticular mass Non-rhabdomyosarcoma pathway, still needs sarcoma-center local control